24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol

Respiratory Medicine

Volumn 104, Issue 11, 2010, Pages 1629-1637

  Sugihara, Naruhiko ^a   Kanada, Shigeto ^b   Haida, Michiko ^c   Ichinose, Masakazu ^d   Adachi, Mitsuru ^e   Hosoe, Motoi ^f   Emery, Charlotte ^g   Higgins, Mark ^g   Kramer, Benjamin ^h  

^a Jinyukai Healthcare Corporation   (Japan)

^b Henshinkai Healthcare Corporation   (Japan)

^c Hanzomon Hospital   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY   (Japan)

^f NOVARTIS PHARMA K K   (Japan)

^g NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asthma; Bronchodilator; Corticosteroids; Indacaterol; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; INDACATEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; PLACEBO; SALMETEROL; SHORT ACTING DRUG; XANTHINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INJURY; INTOXICATION; JAPANESE; LUNG TOXICITY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; JAPAN; MALE; MIDDLE AGED; PLACEBOS; PRACTICE GUIDELINES AS TOPIC; QUINOLONES; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957115277     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.06.011     Document Type: Article

References (31)

1. H. Chen, M.K. Gould, and P.D. Blanc Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease J Allergy Clin Immunol 120 2007 396 402
2. J.K. Schmier, R. Manjunath, M.T. Halpern, M.L. Jones, K. Thompson, and G.B. Diette The impact of inadequately controlled asthma in urban children on quality of life and productivity Ann Allergy Asthma Immunol 98 2007 245 251
3. S. Nishima, H. Chisaka, and T. Fujiwara Surveys on the prevalence of pediatric bronchial asthma in Japan: a comparison between the 1982, 1992 and 2002 surveys conducted in the same region using the same methodology Allergol Int 58 2009 37 53
4. S.H. Downs, G.B. Marks, R. Sporik, E.G. Belosouva, N.G. Car, and J.K. Peat Continued increase in the prevalence of asthma and atopy Arch Dis Child 84 2001 20 23
5. H.R. Anderson, R. Ruggles, and D.P. Strachan Trends in prevalence of symptoms of asthma, hay fever, and eczema in 12-14 year olds in the British Isles, 1995-2002: questionnaire survey Br Med J 328 2004 1052 1053
6. M.N. Upton, A. McConnachie, and C.L. Hart Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring Br Med J 321 2000 88 92
7. Japanese Society of Allergology Asthma prevention and management guideline 2006 2006 Kyowakikaku Japan
8. Guidelines for the diagnosis and management of asthma. Expert panel report 3, updated 2007 http://www.nhlbi.nih.gov/guidelines/asthma/ [accessed 25.02.10]
9. Global initiative for asthma. Global strategy for asthma management and prevention, updated 2009 http://www.ginasthma.org [accessed 25.02.10]
10. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005;4:5-186. Art. No.: CD005535.
11. B.G. Bender Overcoming barriers to nonadherence in asthma treatment J Allergy Clin Immunol 6 2002 S554 S559
12. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296-310
13. J. Schaanning, J. Vilsvik, A.H. Henriksen, and G. Bratten Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction Ann Allergy Asthma Immunol 76 1996 57 60
14. A. Wallin, T. Sandstrom, L. Rosenhall, and B. Melander Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma Thorax 48 1993 611 614
15. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices J Pharmacol Exp Ther 324 2008 270 275
16. C. Battram, S.J. Charlton, and B. Cuenoud In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1- hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action J Pharmacol Exp Ther 317 2006 762 770
17. A.G. Chuchalin, A.N. Tsoi, and K. Richter Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study Respir Med 101 2007 2065 2075
18. L.J. Brookman, L.J. Knowles, M. Barbier, B. Elharrar, R. Fuhr, and S. Pascoe Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma Curr Med Res Opin 23 2007 3113 3122
19. C. LaForce, M. Alexander, and R. Deckelmann Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study Allergy 63 2008 103 111
20. K.M. Beeh, E. Derom, F. Kanniess, R. Cameron, M. Higgins, and A. Van As Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma Eur Respir J 29 2007 871 878
21. C. LaForce, P. Korenblat, P. Osborne, F. Dong, and M. Higgins 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol Curr Med Res Opin 25 2009 2353 2359
22. Clinical trials.gov [homepage on internet]. Clinical trial results http://www.clinicaltrials.gov/ct2/results?term=NCT00403754 [accessed 10.11.08]
23. 2- agonist, in patients with asthma: a dose-ranging study J Asthma 45 2008 887 892
24. J. Morganroth Cardiac repolarization and the safety of new drugs defined by electrocardiography Clin Pharmacol Ther 81 2007 108 113
25. D.S. Pearlman, L. Greos, C. LaForce, C.J. Orevillo, R. Owen, and M. Higgins Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma Ann Allergy Asthma Immunol 101 2008 90 95
26. C.M. Drysdale, D.W. McGraw, C.B. Stack, J.C. Stephens, R.S. Judson, K. Nandabalan, K. Arnold, G. Ruano, and S.B. Liggett Complex promoter and coding region b2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness Proc Natl Acad Sci USA 97 2000 10483 10488
27. M.E. Wechsler, E. Lehman, S.C. Lazarus, R.F. Lemanske Jr., H.A. Boushey, A. Deykin, J.V. Fahy, C.A. Sorkness, V.M. Chinchilli, T.J. Craig, E. DiMango, M. Kraft, F. Leone, R.J. Martin, S.P. Peters, S.J. Szefler, W. Liu, E. Israel National Heart, Lung, and Blood Institute's Asthma Clinical Research Network β-Adrenergic receptor polymorphisms and response to salmeterol Am J Resp Crit Care Med 173 2006 519 526
28. E.R. Bleecker, H.S. Nelson, M. Kraft, J. Corren, D.A. Meyers, S.W. Yancey, W.H. Anderson, A.H. Emmett, and H.G. Ortega Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate Am J Respir Crit Care Med 18 2010 676 687
29. R. Aalbers, J. Ayres, V. Backer, M. Decramer, P.A. Lier, P. Magyar, J. Malolepszy, R. Ruffin, and G.W. Sybrecht Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Eur Respir J 19 2002 936 943
30. Y. Minakata, H. Iijima, T. Takahashi, M. Miura, H. Ogawa, K. Kimura, T. Koga, M. Kinoshita, T. Tsuda, H. Aizawa, and M. Ichinose Efficacy and safety of formoterol in Japanese patients with COPD Intern Med 47 2008 217 223
31. W.H. Yang, J.B. Martinot, and P. Pohunek Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study Ann Allergy Asthma Immunol 99 2007 555 561